2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDisease
2018
Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018, 24: 2272-2277. PMID: 29718223, DOI: 10.1093/ibd/izy133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiological TherapyColitis, UlcerativeCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrognosisProspective StudiesRetrospective StudiesTreatment OutcomeTuberculin TestConceptsLatent tuberculosis infectionInflammatory bowel diseaseTuberculin skin testBiologic therapyLTBI treatmentIBD patientsTuberculosis reactivationBowel diseaseTuberculosis infectionLTBI treatment regimenReactivation of TBRisk of reactivationInterferon-gamma releaseOutcome of treatmentStudy inclusion criteriaMedian annual riskAdalimumab monotherapyIsoniazid therapyTB reactivationCertolizumab pegolPrimary outcomeRetrospective reviewTreatment regimenMedian timeGamma release